Hepatic proteome analysis of Atlantic salmon (Salmo salar) after exposure to environmental concentrations of human pharmaceuticals

• Main Authors: Hampel, Miriam, Alonso, Esteban, Aparicio Gómez, Irene, Santos Morcillo, Juan Luis, Leaver, Michael
• Other Authors: Universidad de Sevilla. Departamento de Química Analítica, Universidad de Sevilla. FQM344: Análisis Químico Industrial y Medioambiental, European Union (UE). FP6
• Format: Article in Journal/Newspaper
• Language: English
• Published: Molecular & Cellular Proteomics 2018
• Subjects: Romero; Atlantic salmon; Salmo salar
• Online Access: https://idus.us.es/xmlui/handle//11441/80129

Pharmaceuticals are pseudopersistent aquatic pollutants with unknown effects at environmentally relevant concentrations. Atlantic salmon (Salmo salar) were exposed to Acetaminophen: 54.77 ± 34.67; Atenolol: 11.08 ± 7.98, and Carbamazepine: 7.85 ± 0.13 μg·L−1 for 5 days. After Acetaminophen treatment, 19 proteins were differently expressed, of which 11 were significant with respect to the control group (eight up-regulated and three down-regulated). After Atenolol treatment, seven differently expressed proteins were obtained in comparison with the control, of which six could be identified (four up-regulated and two down-regulated). Carbamazepine exposure resulted in 15 differently expressed proteins compared with the control, with 10 of them identified (seven up-regulated and three down-regulated). Out of these, three features were common between Acetaminophen and Carbamazepine and one between Carbamazepine and Atenolol. One feature was common across all treatments. Principal component analysis and heat map clustering showed a clear grouping of the variability caused by the applied treatments. The obtained data suggest (1) that exposure to environmentally relevant concentrations of the pharmaceuticals alters the hepatic protein expression profile of the Atlantic salmon; and (2) the existence of treatment specific processes that may be useful for biomarker development. Dr Alberto Pascual Bravo, Raquel Gómez Díaz, y Dr Antonio Romero Ruíz del Instituto de Biomedicina (IBIS-CSIC) en Sevilla Marie Curie (Proposal N° EIF-039691-SALMONPHARM, FP6-2005-Mobility-5)